1. Case Report of Domiciliary Treatment with Tolvaptan in Patients with Advanced Heart Failure and Persistent Hyponatremia
- Author
-
Alberto Esteban Fern, Nahikari Salterain Gonzalez, and Juan J Gavira Gomez
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,valvular heart disease ,Tolvaptan ,Cardiomyopathy ,nutritional and metabolic diseases ,Atrial fibrillation ,medicine.disease ,Coronary artery disease ,Heart failure ,Internal medicine ,medicine ,Cardiology ,Hemodialysis ,Intensive care medicine ,Hyponatremia ,business ,medicine.drug - Abstract
Management of patients with advanced heart failure and persistent hyponatremia remains a difficult challenge today. Classical treatment is not always enough, not only because of diuretics resistance, but also because of the natural course of heart failure and several comorbidities. Tolvaptan, a V2 receptor inhibitor in the kidneys, has demonstrated its utility and safety in refractory hyponatremia correction in patients with decompensated heart failure, but there is little experience about its use in management of chronic hyponatremia. We present a report of a case series with long term domiciliary treatment with Tolvaptan followed up in a Heart Failure unit.
- Published
- 2015
- Full Text
- View/download PDF